StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck proQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M)

QuarterlyAnnual
Latest, Q2 2026
235
Period ended Jun 30, 2026
Change on a year earlier
-13.9%
273 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026235-13.9%Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Q1 2026Mar 31, 2026198+63.6%Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 2025262+29.1%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2025Sep 30, 2025273-0.4%Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗
Q2 2025Jun 30, 2025273+14.2%Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Q1 2025Mar 31, 2025121-40.7%Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 2024203+5.7%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2024Sep 30, 2024274+2.6%Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗
Q2 2024Jun 30, 2024239+7.7%Form 10-Q (mrk-20250630.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024204+7.4%Form 10-Q (mrk-20250331.htm, filed 2025-05-02) ↗
Q4 2023Dec 31, 2023192-3.5%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Q3 2023Sep 30, 2023267+1.1%Form 10-Q (mrk-20240930.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 2023222+3.7%Form 10-Q (mrk-20240630.htm, filed 2024-08-05) ↗
Q1 2023Mar 31, 2023190+17.3%Form 10-Q (mrk-20240331.htm, filed 2024-05-03) ↗
Q4 2022Dec 31, 2022199+13.7%Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗
Q3 2022Sep 30, 2022264+8.2%Form 10-Q (mrk-20230930.htm, filed 2023-11-03) ↗

Breakdown

What makes up proquad (measles, mumps, rubella and varicella virus vaccine) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_proquad

See every metric in the Merck KPI table. Data updated Oct 26, 2026.